← Browse by Condition
Medical Condition
idh1 mutation
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 1, Phase 2
NCT06161974 Phase 2
Recruiting
Study of Olutasidenib and Temozolomide in HGG
Enrollment
60 pts
Location
United States, Austr...
Sponsor
Rigel Pharmaceuticals
NCT06611839 Phase 1, Phase 2
Recruiting
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
Enrollment
29 pts
Location
China
Sponsor
Institute of Hematology & Bloo...